Prognostic Score To Predict Major Complications After Pancreaticoduodenectomy

This study has been completed.
Sponsor:
Information provided by:
Università Vita-Salute San Raffaele
ClinicalTrials.gov Identifier:
NCT01278381
First received: January 14, 2011
Last updated: NA
Last verified: November 2010
History: No changes posted
  Purpose

Pancreaticoduodenectomy (PD) still carries a high rate of severe postoperative complications. No score is currently available to help identify the patient's surgical risk. The purpose of this study was to develop and validate a prognostic score to predict major postoperative complications after PD.


Condition Intervention
Pancreatic Neoplasm
Procedure: Pancreaticoduodenectomy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A PROGNOSTIC SCORE TO PREDICT MAJOR COMPLICATIONS AFTER PANCREATICODUODENECTOMY.

Resource links provided by NLM:


Further study details as provided by Università Vita-Salute San Raffaele:

Primary Outcome Measures:
  • Major Complication rate [ Time Frame: Postoperative. Until 30 days after discharge ] [ Designated as safety issue: No ]
    Clavien-Dindo grade III to V complications considered as major


Enrollment: 700
Study Start Date: January 2002
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pancreaticoduodenectomy (PD)
Patients undergoing PD from 2002 to 2010
Procedure: Pancreaticoduodenectomy
Resection of pancreatic lesion

Detailed Description:

The investigators prospectively collected in an electronic database preoperative, intraoperative and outcome data of 700 patients undergoing PD in our Institution from 2002 to 2010. The investigators used a multivariate logistic regression analysis to create a new score to predict severe complications defined as Clavien-Dindo classification III, IV and V. The score was developed using a random two-thirds of the population (469 patients), and was then validated and calibrated in the remaining third of the patients (231).

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

700 patients undergoing pancreaticoduodenectomy in our Institution from 2002 to 2010

Criteria

Inclusion Criteria:

- Patients undergoing pancreaticoduodenectomy in our Institution

Exclusion Criteria:

  • Metastatic disease
  • Patient not suitable for surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01278381

Locations
Italy
San Raffaele Hospital
Milan, Italy, 20132
Sponsors and Collaborators
Università Vita-Salute San Raffaele
Investigators
Principal Investigator: Marco Braga, MD Università Vita-Salute San Raffaele
  More Information

No publications provided

Responsible Party: Marco Braga, MD, Università Vita-Salute San Raffaele
ClinicalTrials.gov Identifier: NCT01278381     History of Changes
Other Study ID Numbers: PANCREATICODUODENECTOMY_SCORE
Study First Received: January 14, 2011
Last Updated: January 14, 2011
Health Authority: Italy: Ministry of Health

Keywords provided by Università Vita-Salute San Raffaele:
pancreas, pancreaticoduodenectomy, major complications

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on September 30, 2014